How did our management miss the mark so badly.

Discussion in 'Collegium Pharmaceutical' started by anonymous, Apr 15, 2018 at 10:07 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


    They told you you were special because you sell a CII, you believe it. Cute. What exactly does it take to sell a CII? Managed care makes your sales.
     

  2. anonymous

    anonymous Guest

    Clearly you don’t work here or have a clue about what it takes to sell a CII. Even with insurance coverage there are so many obstacles to getting a prescription filled! But if you don’t work in pain you will have no idea!! So I’ll save my breath!
     
  3. anonymous

    anonymous Guest

    You guys really just cannot sell!

    Net Product Revenues were $63.7 million for the quarter ended March 31, 2018 (the “2018 Quarter”) compared to $2.2 million for the quarter ended March 31, 2017 (the “2017 Quarter”). In the 2018 Quarter, net product revenue was $15.8 million for Xtampza and $47.9 million for the Nucynta franchise.

    Net loss for the 2018 Quarter was $18.7 million, or $0.57 per share (basic and diluted), as compared to net loss of $23.1 million, or $0.79 per share (basic and diluted), for the 2017 Quarter. Net loss includes stock-based compensation expense of $2.7 million and $1.8 million for the 2018 Quarter and 2017 Quarter, respectively. Net loss for the 2018 Quarter includes a non-cash interest charge of $5.5 million associated with accounting for Nucynta.
     
  4. anonymous

    anonymous Guest

     
  5. anonymous

    anonymous Guest


    Been selling CII’s a long time and now Xtampza. You are not special, you are just lapping up what they are feeding you.
     
  6. anonymous

    anonymous Guest

    Could it be that the new middle managers are letting go of their representatives, just because they are too inept to develop another team, and hiring reps from their former companies? Could it be that the focus changes every month on priorities? Most people are reeling trying to figure out which priority is this month's focus. And then, half of our group has already been displaced, so there is that feeling of doom that is so fun to work with.
     
  7. anonymous

    anonymous Guest

    Stock is at $19.98/share! The financial community agrees.
     
  8. anonymous

    anonymous Guest

    Quarterly numbers do not look good!
    Another restructuring on the way, they have to say something.
    Also a new message and new ad campaign.

    Holy Toledo!
     
  9. anonymous

    anonymous Guest

    Hahaha right.
    Just another Wall Street poster who is short our stock, trying to scare everyone.
    Go back to your hole, you miserable immoral being.